Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 15, 2025
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments
On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025
Read more at globenewswire.com
